<fieldset id="zrneb"></fieldset><rp id="zrneb"></rp>

Umbralisib NEW

Price	$41	$59	$97
Package	1mg	2mg	5mg

Min. Order:
Supply Ability:	10g
Update Time:	2024-11-19

Product Details

Product Name: Umbralisib	CAS No.: 1532533-67-7
Purity: 99.83%	Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

Name	Umbralisib
Description	Umbralisib (TGR 1202) is a PI3Kδ inhibitor.
In vitro	Umbralisib and carfilzomib synergistically kill blood cancer cells through disrupting the 4E-BP1-eIF4F-c-Myc axis. Umbralisib and carfilzomib in combination synergistically and selectively silence the c-Myc and E2F transcription programs. Umbralisib (15-50 μM) potently represses the expression of c-Myc in the DLBCL cell line LY7, and is uniquely characterized with structural features suitable for targeting CK1ε in lymphoma cells.
In vivo	In a subcutaneous xenograft model of T-cell acute lymphoblastic leukemia (T-ALL) in NOD/SCID mice using the MOLT-4 cell line, TGR-1202 (150 mg/kg, daily p.o.) significantly shrinks the tumors by day 25.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 91 mg/mL (159.2 mM)
Keywords	inhibit \| lymphocytic leukemia \| lymphoma \| RP-5264 \| CLL T cells \| Inhibitor \| haematological malignancies \| cancer \| orally active \| RP 5264 \| PI3K \| Phosphoinositide 3-kinase \| Umbralisib \| Casein Kinase
Inhibitors Related	Myricetin \| Erucic acid \| Sapanisertib \| (2S,3R,4S)-4-Hydroxyisoleucine \| Duvelisib (R enantiomer) hydrochloride \| Isoprenaline hydrochloride \| Quercetin \| GDC0084 \| Quercetin Dihydrate \| Apilimod \| LY294002 \| Idelalisib
Related Compound Libraries	Bioactive Compound Library \| Anti-Cancer Clinical Compound Library \| Inhibitor Library \| FDA-Approved Kinase Inhibitor Library \| Anti-Cancer Approved Drug Library \| FDA-Approved Drug Library \| Anti-Aging Compound Library \| Bioactive Compounds Library Max \| Anti-Cancer Drug Library \| Anti-Cancer Active Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.